DiaCarta Receives CE/IVD for its New COVID 19 test that Identifies Delta Plus and New Variants
UF Innovate | Sid Martin Biotech alum DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy, announced that its new QuantiVirus™ SARS-CoV-2 Variant Detection Test received the CE/IVD marking and therefore, can now be commercialized within the EU and rest of the world.
DiaCarta’s Novel XNA Technology Rapidly Detects Raging New SARS-CoV-2 Variants
UF Innovate | Sid Martin Biotech alum DiaCarta Inc. announced the publication of a study to rapidly detect new COVID-19 variants in MedRxiV.
